Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

CAPS Rating: 3 out of 5

The Company is a biopharmaceutical company that discovers, develops, and intends to commercialize pharmaceutical products for the treatment of serious medical conditions.


Player Avatar TMFUltraLong (99.95) Submitted: 9/9/2011 2:33:18 AM : Underperform Start Price: $68.67 REGN Score: +12.68

Very simply, I don't see Eylea being worth this much. Sure the data has shown its more effective than Avastin, but a $6.6 billion price tag and even in a utopian view maybe 10 times 2012 sales just seems unrealisitc. Arcalyst sales are flat and expenses are rising in part because of Eylea. This company is priced for perfection and all the shareholders are counting their chickens.... but I've yet to see a single egg hatch yet. TMFUltraLong

Member Avatar ValentinoAmoro (< 20) Submitted: 9/21/2011 2:37:10 PM
Recs: 0

Looks like Avastin's rival is being dropped by the Department of Veterans.

Featured Broker Partners